The Motley Fool on MSN
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down ...
Key TakeawaysModerna jumped 9% after Piper Sandler raised its price target to $305 from $230, following Friday’s ...
Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large ...
It's a tremendous sign of success for the vaccine, but it's also a personalized vaccine. That means it can't simply be ...
Nov 6 (Reuters) - Moderna lifted its full-year revenue forecast on Friday, after strong international demand for its COVID-19 ...
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the ...
Moderna released full data on its closely watched cancer vaccine developed with Merck.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Motley Fool on MSN
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results